News

Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced plans for its Phase 3 and Phase 4 clinical development of MIN-101, a drug targeting negative symptoms in schizophrenia patients.  Following a recent “end-of-Phase 2” meeting with the U.S. Food and Drug Administration (FDA), the Company`s next step is the planned initiation of a pivotal Phase 3 trial with MIN-101 in the second half of 2017.

2017-06-20T16:12:58+00:00